Navigation Links
Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
Date:12/4/2012

at MANF, which is selectively upregulated by glial cells in response to ischemia-induced neural injury and protects brain cells from chemically induced brain injury, will play a role in protecting brain cells from injury within the context of Traumatic Brain Injury.

About Amarantus Bioscience, Inc.

Amarantus Bioscience, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Am
'/>"/>

SOURCE Amarantus Bioscience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
2. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
3. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
6. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
7. Amarantus BioSciences Secures $1.1 Million in Financing
8. Amarantus BioSciences Issues CEO Letter to Shareholders
9. Amarantus BioSciences Wins MANF Patent Challenge in Europe
10. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
11. Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Many factors impact tissues targeting such as protein ... the blood-tissue barrier. Even when tissue disposition is achieved, ... tissue rather than the total tissue concentration. , A ... guide lead optimization, predict in vivo activity in animal ... impact the likely human clinical dose. , In this ...
(Date:5/24/2013)... May 24, 2013 Vestiage, Inc. ... company focused on science-based research and development, sales ... cosmeceuticals and nutraceuticals, announced today that it is ... for the sale of Reluma Skin Illuminating Facial ... and application by sending an email to info(at)vestiageinc(dot)com ...
(Date:5/23/2013)... CAMBRIDGE, England , May 24, 2013 ... von Mundipharma angefertigt – Bei der ... Version , 91 % der Teilnehmer einer ... obwohl nur 20 % laut GINA [*] -Definition [1] ... zeigt, dass Menschen mit Asthma generell einer von vier ...
(Date:5/23/2013)... 23, 2013 Venaxis, Inc. (Nasdaq:   APPY), ... obtaining FDA clearance and commercializing its rapid, protein biomarker-based ... of an underwritten public offering of 10,000,000 shares of ... shares of its common stock at an exercise price ... price of $1.25 per share and related warrant.  Venaxis ...
Breaking Biology Technology:DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... other states jockeyed for position on Business Facilities ... ranking as best in the Midwest and No. 4 ... bioscience industry . , (Logo: ... ranking is in part due to updated estimates of ...
... iPierian, Inc., a biopharmaceutical company focused on changing the ... of cellular reprogramming, today announced that it has been ... of Health (NIH) Grand Opportunities (GO) grant awarded to ... two-year span, will be used to generate amyotrophic lateral ...
... Inc. (Nasdaq CM: CRTX), a specialty pharmaceutical company focused ... the respiratory and related markets, today announced that it ... on Wednesday, November 4, 2009, to discuss its financial ... Management will also provide an update on the Company,s ...
Cached Biology Technology:Ohio Bioscience Industry Leads Midwest, Among Best in Nation as Investment Destination 2iPierian to Collaborate With Johns Hopkins University on $3.7 Million NIH Grand Opportunities Grant 2Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call 2Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call 3
(Date:5/23/2013)... the interplay of brain chemicals which help us pay ... BBSRC. , By changing the way neurons respond ... these changes can affect the strength of a neuronal ... response. , Lead author Alex Thiele, Professor ... you can make yourself better heard by speaking louder ...
(Date:5/22/2013)... to improve durability in fuel cell powered buses, ... discovered links between electrode degradation processes and bus ... effects of electrode degradation stressors in the operating ... , The findings of the study, led by ... in a long-term study at Burnaby-based Ballard Power ...
(Date:5/22/2013)... engineering drastically reduces the time and effort needed ... of biotechnology, scientists are reporting. Published in the ... paves the way for more rapid development of ... other activities. , Keith Shearwin and colleagues explain ... genetic material DNA into a bacterium,s genome is ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2
... is the champion of all gliding mammals, able to ... length of two football fields, execute 90-degree turns and ... in Singapore, the United Kingdom and at the University ... with the help of a miniature backpack outfitted with ...
... availability of new genome sequencing technology has prompted ... intriguing hypothesis about how agricultures early beginnings may ... Boris Vinatzer, assistant professor of plant pathology, physiology, ... and Life Sciences, has received a $1 million, ...
... YORK (FEBRUARY 7, 2008) Madagascars turtles and tortoises, ... will continue to crawl steadily toward extinction unless major ... by the Wildlife Conservation Society and other groups. ... capital city Antananarivo, said there is still hope to ...
Cached Biology News:Accelerometer backpacks aid study of gliding behavior in the 'flying' lemur 2Accelerometer backpacks aid study of gliding behavior in the 'flying' lemur 3Tomato pathogen genome may offer clues about bacterial evolution at dawn of agriculture 2Madagascar's tortoises are crawling toward extinction, groups say 2
Request Info...
... 0 (or Cap 0-like) RNA into Cap ... been shown to increase in vivo translation ... is seen in Cap 0 structures created ... well as those Cap 0 structures created ...
Form: Ready to use Applications: ELISA...
RABBIT ANTI HALOPERIDOL...
Biology Products: